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Data are limited on the attributable outcomes of Clostrid-
ium diffi cile–associated disease (CDAD), particularly in 
CDAD-endemic settings. We conducted a retrospective co-
hort study of nonsurgical inpatients admitted for >48 hours 
in 2003 (N = 18,050). The adjusted hazard ratios for read-
mission (hazard ratio 2.19, 95% confi dence interval [CI] 
1.87–2.55) and deaths within 180 days (hazard ratio 1.23, 
95% CI 1.03–1.46) were signifi cantly different among CDAD 
case-patients and noncase patients. In a propensity score 
matched-pairs analysis that used a nested subset of the 
cohort (N = 706), attributable length of stay attributable to 
CDAD was 2.8 days, attributable readmission at 180 days 
was 19.3%, and attributable death at 180 days was 5.7%. 
CDAD patients were signifi cantly more likely than controls to 
be discharged to a long-term-care facility or outside hospital. 
Even in a nonoutbreak setting, CDAD had a statistically sig-
nifi cant negative impact on patient illness and death, and the 
impact of CDAD persisted beyond hospital discharge.
Clostridium diffi cile–associated disease (CDAD) is an increasingly common cause of hospital-associated di-
arrhea (1,2). The emerging NAP1 strain of C. diffi cile has 
been associated with numerous outbreaks and appears to 
be more virulent than other endemic and epidemic C. dif-
fi cile strains (3–9). Despite the increasing importance of 
this pathogen, few data exist on outcomes attributable to 
CDAD (10–14). The attributable mortality for CDAD has 
recently been estimated at 6.9% and 16.7% (9,12). How-
ever, these studies were performed during CDAD out-
breaks caused by the NAP1 strain. Published estimates of 
CDAD-attributable deaths in disease-endemic settings are 
much lower (1.2%–1.5%) (10,13). Kyne et al. did not fi nd 
endemic CDAD to be an independent predictor of death 
within 1 year of CDAD, but that study was relatively small 
(47 CDAD cases) (11). Thus, additional data with larger 
sample sizes are needed to determine outcomes associated 
with CDAD in nonoutbreak settings. With a large cohort 
of CDAD patients at a tertiary-care center, we evaluated 
CDAD outcomes including length of stay, hospital dis-
charge status, time-to-readmission, and deaths in a CDAD-
endemic setting. 
Methods
This study was conducted at Barnes-Jewish Hospi-
tal (BJH), a 1,250-bed, tertiary-care academic hospital in 
St. Louis, Missouri. Eligibility was limited to nonsurgical 
patients admitted for >48 hours from January 1 through 
December 31, 2003. Nonsurgical patients were defi ned as 
those without operating room costs. Surgical patients were 
excluded because of their heterogeneity. Specifi cally, risk 
factors for length of stay, readmission to the hospital, and 
death were different in this population compared with other 
hospitalized patients. Data were primarily collected from 
the hospital’s Medical Informatics database. The database 
was queried to collect patient demographics; admission and 
discharge dates; International Classifi cation of Diseases, 
9th edition, Clinical Modifi cation (ICD-9-CM), diagno-
sis and procedure codes (online Appendix, available from 
www.cdc.gov/EID/content/14/7/1031-app.htm); inpatient 
medication orders; vital signs; and laboratory results, in-
cluding C. diffi cile toxin assay results. The Medical Infor-
matics database was also queried to ascertain date of death. 
Patients without a death date in the database were screened 
for death by reviewing the Social Security Death Index.
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For each patient, a modifi ed APACHE II Acute Phys-
iology Score (APS) was calculated to adjust for severity 
of illness (15). The APS was based on laboratory results 
and vital signs collected within 24 hours of admission. The 
score was modifi ed because data for respiratory rates and 
Glasgow coma scores were unavailable electronically. In 
addition, the Charlson-Deyo method was used to classify 
co-existing conditions (16,17). Albumin levels within 24 
hours of admission were collected and categorized into 
normal (>3.5 g/dL), low (2.5–3.5 g/dL), and very low (<2.5 
g/dL). Multiple imputation methods were used to impute 
albumin levels for patients without recorded values (18). 
For CDAD case-patients, only medication and intensive-
care unit exposures before the patient’s fi rst positive stool 
toxin assay were included in analyses.
Case Defi nition
CDAD case-patients were defi ned as inpatients with 
positive C. diffi cile stool toxin assays (TechLab, Blacks-
burg, VA, USA). The microbiology laboratory only per-
forms toxin tests on unformed stool, so all patients with 
a positive result for toxin were considered case-patients. 
Both community-onset and hospital-onset CDAD case-
patients were included in the analyses.
Analyses were performed on the full cohort and a nest-
ed case–control population. The fi rst component was a ret-
rospective cohort. For CDAD patients, the admission date 
when the patient’s CDAD was fi rst identifi ed was used as 
the index admission. For noncases with >1 admission dur-
ing the study period, 1 admission was randomly selected as 
the index admission. The nested case–control population 
consisted of propensity score matched cases and controls 
from patients identifi ed in the cohort.
Cohort
Data Analysis
Survival was defi ned as the number of days from the 
index hospital admission until death. Survival was cen-
sored at 180 days. Time to readmission was calculated as 
the number of days between the index hospitalization dis-
charge date and the date of the subsequent admission to 
BJH, if applicable. Days until readmission were censored 
at death or 180 days, whichever occurred fi rst.
Fisher exact, χ2, and Mann-Whitney U tests were 
used to compare characteristics of patients with and with-
out CDAD. Time-to-event methods were used to estimate 
the effect of CDAD on 180-day survival and time-to-re-
admission. Patients who died during the index hospitaliza-
tion were excluded from the time-to-readmission analysis. 
Kaplan-Meier analysis was used to evaluate the unadjusted 
relationships between CDAD and time-to-event outcomes. 
Cox proportional hazards regression was used to estimate 
unadjusted and adjusted hazard ratios and 95% confi dence 
intervals (CIs). All variables with biologic plausibility or 
p<0.15 in the univariate analysis were considered in the 
multivariable Cox regression analysis by using backward 
stepwise selection. Variables were sequentially removed 
from the fi nal model, starting with the variable most weak-
ly associated with the outcome. The signifi cance of individ-
ual covariates was determined by using a Wald statistic of 
p<0.05. The proportional hazards assumption was verifi ed 
by assessing the parallel nature of curves in log-log plots.
Propensity Score Matched-Pairs Analysis
The second component of this study was a propensity 
score matched-pairs analysis of outcomes attributable to 
CDAD. This study design complemented the cohort by 
enabling analyses that could not be conducted in the en-
tire cohort, specifi cally hospital discharge status, attribut-
able length of stay, attributable time-to-readmission, and 
attributable death. Hospital discharge status could not be 
analyzed for the entire cohort because manual review of 
medical records was required to determine the discharge 
location of each patient. The large size of the cohort pro-
hibited this analysis. In addition, survival and time-to-re-
admission estimates generated in the cohort analysis were 
validated in the matched-pairs analysis.
Cases and a subset of controls were selected from the 
primary cohort for the matched-pairs analysis. CDAD case-
patients were matched to controls based on their propensity 
for CDAD to develop. Patient-specifi c probabilities of de-
veloping CDAD were predicted by a full logistic regres-
sion model adjusted for all variables suspected to impact 
the risk of developing CDAD (online Appendix). Variables 
with p<0.05 in univariate analysis or biologic plausibility 
were included in the full logistic regression model. CDAD 
case-patients and controls were matched by a 1:1 ratio that 
used the nearest-neighbor method within calipers of 0.015 
standard deviations (19). CDAD cases without an available 
nearest-neighbor control were excluded from the analysis. 
Chi-square, Fisher exact, and Mann Whitney U tests were 
used, as appropriate, to compare characteristics of CDAD 
case-patients and controls.
Medical records were reviewed for all CDAD case-
patients and controls to determine hospital discharge loca-
tion for each patient. Patients were categorized as being 
discharged to home, to a long-term-care facility, or to an 
outside hospital or dying in the hospital. Long-term-care 
facility was defi ned as a long-term-care facility, long-term 
acute-care facility/chronic ventilation facility, inpatient 
rehabilitation facility, skilled nursing facility, or nursing 
home. Outside hospital was defi ned as a non-BJH hospital 
or acute-care facility.
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Data Analysis
Median length of stay was determined for CDAD case-
patients and controls. The difference in median pairwise 
length of stay was compared with the Wilcoxon signed-
rank test. Attributable length of stay was calculated as the 
median pairwise difference between CDAD case-patients 
and controls. Frequencies, adjusted odds ratios, and 95% 
CIs were calculated to determine if discharge location was 
associated with CDAD. CDAD-attributable 180-day re-
admission was calculated as the difference in readmission 
between CDAD case-patients and controls. Attributable 
deaths from 0–180 days, 0–60 days, and 61–180 days after 
admission were also calculated by using this method.
The primary survival endpoints of interest were death 
and readmission, which were both censored at 180 days 
or at death. Kaplan-Meier analyses, conducted by using 
log-rank tests, were used to determine relationships be-
tween the survival endpoints and CDAD. Cox propor-
tional hazards regression stratifi ed by matched-pairs was 
used to obtain hazard ratios and 95% CIs. Violation of 
the proportional hazards assumption was verifi ed by the 
crossing nature of curves in the log-log plots. Therefore, 
we used an extended Cox regression model stratifi ed by 
matched-pairs for the periods <60 days and >60 days. The 
breakpoint of 60 days was chosen because the graph of 
survival curves for CDAD case-patients and controls di-
verged at ≈60 days. Violation of the proportional hazards 
assumption was confi rmed by the signifi cance of the coef-
fi cient for the product term between CDAD and <60 days 
and >60 days (20).
All tests were 2-tailed, and p<0.05 was considered 
signifi cant. Statistical analyses were performed with SPSS 
for Windows version 14.0 (SPSS, Inc., Chicago, IL, USA) 
and SAS version 9.1 (SAS Institute, Cary, NC, USA). The 
Washington University Human Studies Committee ap-
proved this project.
Results
Among 18,050 nonsurgical inpatients admitted dur-
ing the 1-year study period, 390 had CDAD and 17,660 
did not. Selected patient characteristics of the cohort are 
summarized in Table 1. CDAD patients were signifi cantly 
older (median 66.0 vs. 52.7 years, p<0.001) more likely to 
be men, and more likely to be Caucasian than were non-
case-patients. CDAD case-patients had a higher severity 
of illness on admission than noncases, as indicated by the 
modifi ed APS. CDAD patients were more likely to have a 
diagnosis of congestive heart failure, chronic obstructive 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 7, July 2008 1033 
Table 1. Baseline characteristics of study cohort, Clostridium difficile–associated disease (N = 18,050)* 
Characteristic 
CDAD case-patients (n = 390), 
no. (%) 
Non–case-patients (n = 17,663),  
no. (%) p value† 
Age, y    
 <45 58 (15) 6,847 (39) <0.001 
 45–65 132 (34) 5,187 (29) 0.06 
 >65 200 (51) 5,626 (32) <0.001 
Male sex 194 (50) 6,704 (38) <0.001 
White race 257 (66) 9,860 (56) <0.001 
Modified APS    
 <2 77 (20) 6,687 (38) <0.001 
 3–4 76 (20) 4,573 (26) 0.004 
 5–6 82 (21) 2,970 (17) 0.028 
 !7 155 (40) 3,430 (19) <0.001 
Liver disease    
 Mild 5 (1) 204 (1) 0.77 
 Moderate to severe 6 (2) 209 (1) 0.47 
Diabetes without chronic complications 70 (18) 2,718 (15) 0.17 
Diabetes with chronic complications 15 (4) 416 (2) 0.06 
Myocardial infarction 26 (7) 1466 (8) 0.25 
Congestive heart failure 97 (25) 2,562 (15) <0.001 
Cerebral vascular disease 16 (4) 882 (5) 0.42 
Chronic obstructive pulmonary disease 90 (23) 2,564 (15) <0.001 
Rheumatologic/collagen vascular disease 11 (3) 361 (2) 0.29 
Peptic ulcer disease 5 (1) 279 (2) 0.64 
Cancer, excluding leukemia or lymphoma 45 (12) 1,283 (7) 0.001 
Leukemia or lymphoma 69 (18) 567 (3) <0.001 
Metastatic solid tumor 33 (9) 936 (5) 0.01 
HIV/AIDS 5 (1) 209 (1) 0.81 
Paraplegia or hemiplegia 8 (2) 223 (1) 0.17 
*CDAD, Clostridium difficile–associated disease; APS, Acute Physiology Score. 
† Fisher exact test, Ȥ2 test. 
RESEARCH
pulmonary disease, cancer, leukemia or lymphoma, and 
metastatic solid tumors.
Of 17,492 patients alive at the index hospitalization 
discharge, 4,207 (24%) were readmitted to BJH within 
180 days. Fifty-two percent of CDAD patients were read-
mitted within 180 days versus 23% of noncases (log-rank 
p<0.001). Univariate and multivariable Cox regression re-
sults for time to readmission are presented in Table 2. The 
adjusted hazard ratio (HR) for readmission within 180 days 
was signifi cantly higher for CDAD case-patients than non-
cases (HR 2.19, 95% CI 1.87–2.55) (Table 2).
By 180 days after hospital admission, 149 (38%) of 
390 CDAD case-patients and 2,150 (12%) 17,660 noncase-
patients had died. In the Kaplan-Meier analysis, the mortal-
ity rate was signifi cantly higher for CDAD case-patients 
than noncases (log rank p<0.001) (Figure 1). Unadjusted 
and adjusted Cox regression results for death within 180 
days of admission (“180-day mortality”) are presented in 
Table 3. The adjusted hazard ratio for 180-day mortality 
was signifi cantly higher for CDAD case-patients than non-
case patients (HR 1.23, 95% CI 1.03–1.46) (Table 3).
The propensity score matched-pairs analysis included 
353 CDAD cases and 353 controls (N = 706). There were 
no signifi cant differences between the matched cases and 
controls after correcting for multiple testing with the Bon-
ferroni procedure. Thirty-seven CDAD case-patients were 
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Table 2. Cox proportional hazards estimate of readmission at 180 d in Clostridium difficile–associated disease (CDAD) study cohort  
(N = 17,492; 4,207 readmissions, 13,285 censored)*† 
Variable Univariate hazard ratio‡ (95% CI) Multivariable hazard ratio ‡ (95% CI) 
CDAD 3.09 (2.95–3.23) 2.19 (1.87–2.55) 
Male sex 1.42 (1.40–1.45) 1.11 (1.05–1.19) 
White race 1.26 (1.23–1.28) 1.06 (1.00–1.13) 
Modified APS 
<2 Reference Reference
 3–4 1.15 (1.12–1.18) 1.10 (1.02–1.20) 
 5–6 1.39 (1.35–1.43) 1.24 (1.13–1.35) 
 !7 1.84 (1.80–1.89) 1.50 (1.37–1.64) 
Albumin, g/dL§ 
 >3.5 Reference Reference
  2.5–3.5 1.05 (1.03–1.08) 0.99 (0.92–1.08) 
  <2.5 1.03 (0.99–1.07) 0.95 (0.80–1.14) 
Liver disease 
  None Reference Reference
  Mild 1.80 (1.67–1.94) 1.44 (1.12–1.83) 
  Moderate to severe 1.79 (1.65–1.94) 1.48 (1.13–1.93) 
Diabetes with chronic complications 1.89 (1.80–1.99) 1.53 (1.30–1.80) 
Diabetes without chronic complications 1.29 (1.26–1.32) 1.10 (1.02–1.19) 
Congestive heart failure 1.60 (1.56–1.64) 1.34 (1.23–1.45) 
Cerebrovascular disease 0.77 (0.74–0.81) 0.74 (0.63–0.87) 
Cancer, excluding leukemia or lymphoma 2.75 (2.67–2.83) 1.90 (1.70–2.13) 
Leukemia or lymphoma 2.31 (2.18–2.45) 1.84 (1.52–2.23) 
Metastatic solid tumor 2.81 (2.71–2.91) 1.66 (1.46–1.90) 
HIV/AIDS 1.74 (1.62–1.87) 1.74 (1.38–2.19) 
ICU admission 1.06 (1.03–1.09) 0.84 (0.76–0.93) 
*CI, confidence interval; APS, Acute Physiology Score; ICU, intensive care unit. 
†The analysis excluded 558 patients who died during the index hospital admission. Nonsignificant variables considered in the model included mechanical 
ventilation, paraplegia/hemiplegia, chronic obstructive pulmonary disease, myocardial infarction, rheumatologic/collagen vascular disease, and peptic 
ulcer disease. 
‡Hazard ratios also adjusted for categorical age (<20, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 
85–89, 90–94, >95 y). 
§7,610 (42%) patients were missing albumin values. Values were imputed by using multiple imputation methods. 
Figure 1. Kaplan-Meier survival estimates for cohort (N = 18,050). 
CDAD, Clostridium diffi cile–associated disease.
C. diffi cile–associated Disease in Nonsurgical Patients
dropped because a nearest-neighbor control was not avail-
able. Unmatched CDAD patients had signifi cantly higher 
modifi ed APS (median = 7.0 vs. 5.0, p<0.001), longer me-
dian length of stay (13.6 days vs. 9.6 days, p = 0.01), and 
higher percentage of deaths at 180 days (59% vs. 36%, p = 
0.01) than matched case-patients.
In the matched-pairs analysis, median length of stay 
was 9.6 days for CDAD patients compared with 5.8 days 
for controls, and the increased attributable length of stay 
for CDAD patients was 2.8 days (Wilcoxon signed-rank 
p<0.001). Among the 706 patients in the matched-pairs anal-
ysis, 445 (63%) were discharged to home and 188 (27%) 
were discharged to a long-term-care facility. Only 7 (1%) 
patients were discharged to an outside hospital; therefore, 
these patients were combined with patients discharged to a 
long-term-care facility in the analysis. CDAD patients were 
signifi cantly more likely than controls to be discharged to 
a long-term-care facility or outside hospital (32% vs. 23%, 
odds ratio 1.62, 95% CI 1.15–2.28, McNemar p = 0.01).
Among 290 matched-pairs with both patient and con-
trol alive at index hospitalization discharge, 148 CDAD 
patients were readmitted to BJH within 180 days compared 
with 92 controls, for an attributable readmission of 19.3% 
(11.4%–27.2%). In the Kaplan-Meier and Cox model anal-
yses, CDAD patients were signifi cantly more likely than 
controls to be readmitted to the hospital within 180 days 
(Figure 2, Table 4).
By 180 days after hospital admission, 127 CDAD 
patients died compared with 107 controls, for an attribut-
able mortality of 5.7% (95% CI –1.3%–12.6%). Although 
CDAD case-patients were no more likely than controls to 
die within 60 days of hospital admission, a divergence in 
survival between CDAD case-patients and controls began 
60 days after hospital admission (Figure 3, Table 4). The 
HR for death from 61–180 days was signifi cantly higher 
for CDAD patients than controls (HR 2.00, 95% CI 1.47–
2.72) (Table 4). Among 223 matched-pairs with both case-
patients and controls alive after day 60, 19.7% of CDAD 
patients and 12.6% of controls died within 180 days for an 
attributable mortality between 61–180 days of 7.2% (95% 
CI 0.4%–14.0%).  
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Table 3. Cox proportional hazards estimate of deaths from Clostridium difficile–associated disease (CDAD) at 180 d in study cohort  
(N = 18,050; 2,299 deaths, 15,751 censored)*† 
Variable Univariate hazard ratio‡ (95% CI) Multivariable hazard ratio‡ (95% CI) 
CDAD 3.55 (3.37–3.75) 1.23 (1.03–1.46) 
Male sex 1.73 (1.68–1.77) 1.17 (1.08–1.27) 
White race 1.65 (1.61–1.70) 1.22 (1.11–1.33) 
Modified APS 
<2 Reference Reference
  3–4 1.41 (1.36–1.47) 1.09 (0.96–1.24) 
  5–6 2.09 (2.00–2.17) 1.30 (1.14–1.49) 
>7 4.11 (3.97–4.25) 1.65 (1.46–1.87) 
Albumin, g/dL§ 
  >3.5 Reference Reference
  2.5–3.5 2.12 (1.90–2.36) 1.62 (1.45–1.82) 
  <2.5 4.77 (3.91–5.81) 2.93 (2.52–3.42) 
Liver disease 
  None Reference Reference
  Mild 3.08 (2.86–3.33) 2.37 (1.85–3.04) 
  Moderate to severe 5.50 (5.17–5.85) 3.76 (3.05–4.64) 
Diabetes with chronic complications 1.47 (1.37–1.58) 1.49 (1.18–1.88) 
Congestive heart failure 1.85 (1.80–1.91) 1.28 (1.15–1.42) 
Cerebrovascular disease 1.68 (1.60–1.76) 1.62 (1.37–1.92) 
Cancer, excluding leukemia or lymphoma 6.42 (6.24–6.61) 2.44 (2.15–2.76) 
Leukemia or  lymphoma 3.17 (2.99–3.38) 4.92 (3.98–6.08) 
Metastatic solid tumor 8.82 (8.57–9.09) 4.41 (3.87–5.03) 
HIV/AIDS 1.77 (1.62–1.95) 2.88 (2.12–3.91) 
Paraplegia/ hemiplegia 1.75 (1.60–1.92) 1.53 (1.12–2.07) 
Mechanical ventilation 6.39 (6.18–6.62) 3.17 (2.71–3.71) 
ICU admission 3.08 (2.99–3.17) 1.31 (1.14–1.50) 
*CI, confidence interval; APS, Acute Physiology Score; ICU, intensive care unit. 
†Nonsignificant variables considered in the model included diabetes without chronic complications, chronic obstructive pulmonary disease, myocardial 
infarction, rheumatologic/collagen vascular disease and peptic ulcer disease. Of 2,299 people who died within 180 d of admission, 1,565 (68%) deaths 
were identified by means of the hospital Medical Informatics database and 734 (32%) were identified with the Social Security Death Index. 
‡Hazard ratios also adjusted for categorical age (<20, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 
85–89, 90–94, t95 y). 
§7,525 (43%) patients were missing albumin values. Values were imputed by using multiple imputation methods. 
RESEARCH
Discussion
The results of this study indicate that CDAD is a ma-
jor contributor to death even in nonoutbreak settings. In this 
CDAD-endemic setting, the disease was associated with a 
23% higher hazard of death within 180 days after hospital 
admission in the multivariable cohort analysis and a 7.2% 
attributable mortality 61–180 days after hospital admission 
in the matched-pairs analysis. Historically, endemic CDAD 
has been reported to be associated with minimal increased 
risk in mortality although NAP1 strain CDAD outbreaks 
have been associated with much higher attributable mortal-
ity (10,11,13). Two studies of CDAD in endemic settings 
reported 1.2%–1.5% inhospital mortality rates from CDAD 
(10,13). Using a multivariable Cox proportional hazards 
model, Kyne et al. found no association between CDAD 
and 1-year mortality, although that study was quite small 
(47 CDAD patients) (11). In contrast, several studies have 
identifi ed increased deaths associated with outbreaks of the 
NAP1 strain. Pepin et al. estimated the 1-year attributable 
mortality of CDAD during an outbreak with the NAP1 strain 
to be 16.7% (9). Hubert et al. reported that CDAD was the 
attributable or contributive cause of death in 8.4% of patients 
infected with a strain of C. diffi cile that had the binary toxin 
and tcdC deletion (21). Loo et al. found CDAD to be the at-
tributable cause of death within 30 days in 6.9% of CDAD 
patients and suspected that CDAD contributed to death in 
another 7.5% of CDAD patients (12). The estimate of 6.9% 
attributable mortality, however, was determined through 
chart review, not through multivariable analyses, and medi-
cal chart review may not be an adequate method to determine 
attributable mortality because of subjectivity (22).
Although the 5.7% 180-day attributable mortality de-
termined in the propensity score matched-pairs analysis 
in our study was not statistically signifi cant, the estimate 
is substantially higher than estimates reported from other 
CDAD-endemic settings. The attributable mortality we re-
port is more consistent with estimates from outbreaks of the 
NAP1 strain and is likely clinically signifi cant. The NAP1 
strain was fi rst identifi ed at BJH during 2005, but the strain 
may have been present during the study period (23). During 
the years 2000–2006 at BJH, there were no apparent in-
creases in hospital-onset CDAD incidence rates or severity 
of CDAD (as measured by the number of colectomies per 
CDAD case per year and by the percentage of patients with 
CDAD who died during hospitalization) (data not shown). 
Thus, the high attributable mortality found in this study has 
important implications for patients: CDAD remains an im-
portant cause of patient death even in a CDAD-endemic 
setting.
Our study showed that CDAD had a delayed impact 
on death. In the matched-pairs analysis, the divergence in 
survival between CDAD cases-patients and controls did 
not begin until >60 days after hospital admission. Within 
60 days of admission, survival was not signifi cantly differ-
ent between CDAD patients and controls, when all but 4 
(1%) patients had been discharged from the hospital. This 
fi nding is consistent with those of 2 recent nested matched 
case–control studies in nonoutbreak settings, in which no 
signifi cant excess deaths were reported after 30 days (24) 
or at discharge (25). Although CDAD can be acutely life-
threatening, delayed death caused by CDAD may not be 
easily recognized as related to the initial CDAD episode. 
CDAD may contribute to a decline in patient function and 
overall illness over time, ultimately leading to death in 
many patients.
The results of the time-to-readmission and discharge 
location analyses further emphasize the negative impact of 
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Figure 2. Kaplan-Meier estimates of time until hospital readmission 
for matched pairs (n = 580). CDAD, Clostridium diffi cile–associated 
disease.
Table 4. Cox proportional hazards model estimates of readmission and death of matched-pairs analysis, Clostridium difficile–
associated disease (CDAD)* 
Variable CDAD case-patients, no. (%) Controls, no. (%) Hazard ratio (95% CI) 
Readmitted within 180 d† 148 (51.0) 92 (31.7) 2.17 (1.59–2.95) 
Deaths at 180 d‡ 127 (36.0) 107 (30.3) 1.22 (0.92–1.61) 
Deaths at 0–60 d‡ 72 (20.4) 75 (21.2) 0.96 (0.54–1.70) 
Deaths at 61–180 d‡ 55 (15.6) 32 (9.1) 2.00 (1.47–2.72) 
*CI, confidence interval. 
†n = 290 matched pairs; 63 matched pairs were excluded because one or both patients in the pair died during the index hospital admission. 
‡n = 353 matched pairs. 
C. diffi cile–associated Disease in Nonsurgical Patients
CDAD. CDAD patients were more than twice as likely to 
be readmitted to BJH within 180 days compared with con-
trols. This fi nding is consistent with our prior fi ndings that 
CDAD contributes to an increase in hospital costs extend-
ing out to at least 180 days (26). CDAD patients were also 
signifi cantly more likely to be discharged to a long-term-
care facility or outside hospital. Few data are available on 
the health of CDAD patients after hospital discharge, and 
future studies following CDAD patients as outpatients over 
an extended period are needed.
Data on the excess length of hospital stay attributable 
to CDAD are limited. Wilcox et al. found that CDAD pa-
tients stayed in the hospital, on average, 21.3 days longer 
than non-CDAD patients; however, the attributable length 
of stay was not calculated (14). O’Brien et al. reported that 
the mean increase in hospitalization among CDAD patients 
was 2.9 days (27). Kyne et al. calculated the attributable 
length of stay at 3.6 days (11), which was comparable to 
the attributable length of stay estimate found in our study 
(2.8 days).
Our study has several limitations, including the ret-
rospective study design. Use of electronic data from the 
hospital’s Medical Informatics database has limitations, 
although use of these data made analysis of such a large co-
hort feasible. Differences seen in observational studies may 
be due to unmeasured confounders. We attempted to ad-
dress this issue by using 2 methods to control for confound-
ing: multivariable regression analyses and propensity score 
matched-pairs analyses. As evident from the Kaplan-Meier 
mortality analyses, the matched-pairs population is a more 
homogeneous population than the cohort. This design al-
lows more precise effect estimation because the association 
between CDAD and the propensity score variables among 
the study participants is eliminated. A strength of the mul-
tivariable regression analyses is the use of all available 
data in the cohort. In the propensity score matched-pairs 
analyses, 37 CDAD cases were excluded because of lack 
of a suitable control. Unmatched case-patients were more 
severely ill than matched case-patients, and their exclusion 
is a limitation of the propensity-score matched-pairs analy-
ses. In the time-to-readmission analyses, we were unable to 
identify readmissions to hospitals other than our institution. 
Finally, surgical patients were excluded from these analy-
ses. Because of this exclusion, the most severely ill CDAD 
patients requiring colectomies (n = 3) were not represented 
in the dataset. The absence of these patients, as well as the 
37 unmatched case-patients, may have resulted in estimates 
of attributable length of stay and death that are biased low.
Data on attributable outcomes associated with CDAD 
are scarce. As previously mentioned, some data on attribut-
able mortality and length of stay exist; however, these fi nd-
ings are limited by lack of adequate controls, small sample 
size, or outbreak settings. Our study provided detailed 
analysis on the effect of CDAD on time-to-readmission. 
Another key strength of this study is the combination of 
2 analytical methods: Cox proportional hazards regres-
sion in the primary cohort and propensity score matched-
pairs analysis. Mortality and time-to-readmission analyses, 
which were conducted in both the cohort and matched-
pairs populations, had remarkably similar results. The re-
sults of this study suggest that endemic CDAD can lead to 
signifi cantly poorer patient outcomes, including increased 
hospital length of stay, death, risk for admission to a long-
term-care facility, and risk for hospital readmission. Even 
when the most severe CDAD cases are not considered, the 
detrimental effect of CDAD on patient health appears to 
extend beyond hospital discharge. Although prospective 
validation of these fi ndings is needed, proper allocation of 
healthcare resources toward prevention of this infection is 
necessary to prevent further illness and death attributable 
to CDAD.
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